Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 15/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129437 | 0.95 | IKZF1 (0.49) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31747465 | 0.93 | CRBN (0.55) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30135733 | 0.92 | CRBN (0.58) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL27099085 | 0.92 | CRBN (0.58) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL23250121 | 0.91 | CRBN (0.50) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL29874231 | 0.91 | CRBN (0.50) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31752706 | 0.91 | CRBN (0.53) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL22581128 | 0.89 | IKZF2 (0.48) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30023739 | 0.89 | IKZF2 (0.48) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31753300 | 0.88 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | CRBN 1/4885IKZF3 759/4885DDB1 1314/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | CRBN 2/4885IKZF3 612/4885DDB1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.